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SCHIZOPHRENIA CARE AND ASSESSMENT
PROGRAM (SCAP): THE IMPACT OF CLINICAL
AND FUNCTIONAL CHARACTERISTICS AND
ANTIPSYCHOTIC MEDICATION TREATMENT
ON OUTPATIENT AND INPATIENT
PSYCHIATRIC UTILIZATION
Russo P1, Palmer LA1,Vasey J2
1The MEDSTAT Group, Inc, Washington, DC, USA; 2The
Pennsylvania State University, State College, PA, USA
OBJECTIVE: Examine the impact of clinical syndrome
and type of antipsychotic medication on outpatient and
inpatient utilization for participants in the U.S. SCAP.
METHODS: Baseline data used to predict 1-year outpa-
tient and inpatient utilization (n = 806). Psychotherapy,
clinic visits, rehabilitation treatment, day treatment and
hospitalizations examined. Presence of antipsychotics
coded for ﬁrst generation (reference group), second gen-
eration, both ﬁrst and second-generation, and no antipsy-
chotic use. Logistic and negative binomial regressions
using predicted values obtained through joint determina-
tion (SURE) of clinical/functional status conducted with
demographic variables as controls.
RESULTS: Persons with combination of ﬁrst and second-
generation antipsychotics exhibited higher likelihood 
(p < 0.001) and greater number of psychotherapy visits
(p < 0.001), higher likelihood of day treatment (p =
0.002) and shorter hospital length of stay (p = 0.03).
Persons prescribed only second-generation antipsychotics
had higher likelihood (p = 0.001) and greater number of
psychotherapy visits (p = 0.03), lower likelihood and
number of clinic visits lower (p = 0.05; p < 0.001) and
higher probability of rehabilitation (p = 0.04). Depression
(MADRS) and functionality (GAF) exhibited an inverse
relationship to number of clinic visits. Higher function-
ing led to lower probability (p = 0.001) of day treatment.
Higher QLS scores associated with higher likelihood of
day treatment (p < 0.001) and fewer inpatient days of care
(0.05).
CONCLUSION: This analysis indicates that antipsy-
chotic type impacts probability and number of outpatient
services and days of inpatient care; impact however is
mixed and warrants further investigation. Clinical and
functional status impact utilization; results suggest a
‘bimodal’ utilization effect. Individuals with higher 
functioning levels may require fewer services to maintain
community functioning; individuals with lower levels of
functioning may not be well enough to participate in 
outpatient services. Findings suggest medication and
functional status are signiﬁcant determinants of inpatient
and outpatient utilization; evaluation of these factors may
lead to better clinical management and policy decision-
making for persons with schizophrenia.
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OBJECTIVE: To estimate incremental cost-effectiveness
(ICE) of donepezil for mild or moderate AD as compared
with option of no treatment in Polish settings.
METHODS: We used Markov model developed by
Naumann et al. Model assumptions: treatment duration
and drug effect, 6 months; cohort of patients initially 
split by 50% into mild and moderate disease states; 50%
of patients on 5mg and 50% on 10mg daily dose of
donepezil. Data on costs by stage of disease including:
medications, medical equipment, home help and commu-
nity nurse, were taken from the Polish Alzheimer’s
Society. Study was conducted from a societal perspective.
Three types of outcome were estimated: expected costs,
years in state less than severe (SLS), and incremental 
costs per additional SLS per treated person over 5 years
projection.
RESULTS: The difference in expected costs per patient
over 12, 24, and 60 months of treatment was: US $634,
$520, and $408, respectively. Patients receiving donepezil
were predicted to spend additional 0.123 year in less than
severe AD compared with untreated patients. Incremen-
tal costs of SLS per treated person was $3,315/year. 
Sensitivity analysis revealed that ICE increased in paral-
lel with the percentage of patients being initially in the
mild AD. The difference in the total expected costs of
treatment was: $355 and $303 when cohort comprised
of 75% and 100% of patients with mild AD, respectively.
In these scenarios additional time spent in SLS AD was
0.151 and 0.179 year and incremental costs of SLS was
$2,364/year and $1,694/year, respectively. When the
duration of treatment and effects were projected for 1
year, incremental costs of SLS was $3,852/year.
CONCLUSION: Donepezil in the treatment of AD is
most cost-effective in mild stage of the disease and its
cost-effectiveness is reduced when treatment lasts >6
months.
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THE EFFECTS OF PANAX GINSENG ON
QUALITY OF LIFE:A PILOT STUDY
Reddy P, Ellis J
University of Connecticut, Storrs, CT, USA
OBJECTIVE: To assess the time-dependent effects of
Panax ginseng on health-related quality of life (HRQOL)
using a general health status questionnaire.
